Cover Image
Market Research Report

India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there

Published by MP Advisors Product code 324902
Published Content info 22 pages
Delivery time: 1-2 business days
Price
Back to Top
India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there
Published: January 21, 2015 Content info: 22 pages
Description

Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have a been a new generation of entrepreneurs who have who ventured into the drug discovery path backed by VC funding and no pharma heritage ! In this Outlook we highlight the names of some select innovation/drug discovery companies who have successfully raised funds to sustain the research, out-licensed some of their assets or are likely to do so in the next 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand the universe further.

Table of Contents
Product Code: 4476

Table of Contents

Company Analysis:

Connexious - Connexios has had a bumpy ride like most Rising stars/drug discovery.

Companies in the biotech sector:

  • Technology Platform
  • Therapy Focus-Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
  • Key Milestones
  • Figure 1: PRODUCTS IN PIPELINE- DIABETES
  • Figure 2: PRODUCTS IN PIPELINE FOR NASH
  • Figure 3: OTHER PROGRAMS
  • Appendix 1: Network Biology Platform for Diabetes and fibrosis
  • Appendix:2 Novel GPR40 agonist
  • CNX-103: Whole body improvement of metabolic health
  • Table 1: Differences Between G-Protein Coupled receptor agonists
  • Table 2: Pipeline Of Gpr Agonist For Treatment Of Type 2 Diabetes

Cellworks - Cellworks (CW) has evolved from a service based company to a drug discovery/development company on the strength of its proprietary Virtual Prototyping platform that allows simulation of cell types//disease in silico.

  • Technology Platform
  • Pipeline
  • Figure 1: Simulation Based personalization
  • Figure 2: Cellworks Therapeutic Programs

Bugworks - Bugworks is a validation of Cellworks simulation in silico Technology Platform where its Bugworks Microbial Platform (BMP) combines functional proteomics with sophisticated semiconductor designe engineering to model and manipulate various bacterial systems.

  • Therapy focus- Serious Hospital Infection
  • Technology Platform
  • Need of the Hour- New Targets= New Antibiotic Class
  • The GAIN Act
  • Figure 1: Drug Development Success For Tb
  • Figure 2: Going Way Froward : focus: Helathcare Associated Infections

Tergene - Tergene's first product in development is a vaccine for pneumonia caused by, Streptococcus pneumonia (pneumococcous). The available vaccine The Pneumococcal Polysaccharide Vaccines (PPV).

  • Development Strategy and Status-
  • Long term plans
  • Vaccine Market
  • Figure 1: sales of currently available vaccines for streptococcus pneumonia
  • Figure 2: Ww Demand Forecast Of Vaccines For Streptococcus Pneumonia
  • Figure 3: Vaccine Market
Back to Top